-
Moleculin Biotech NasdaqCM:MBRX Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 3 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Location: 5300 Memorial Drive, Houston, TX, 77007, United States | Website: https://moleculin.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.435M
Cash
7.716M
Avg Qtr Burn
-5.427M
Short % of Float
7.77%
Insider Ownership
0.71%
Institutional Own.
10.47%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Annamycin + Ara-C (Cytarabine) Details Blood cancer, Cancer, Acute myeloid leukemia | Phase 3 Data readout | |
WP1066 Details Brain tumor, Solid tumor/s, Cancer, Glioblastoma | Phase 1/2 Data readout | |
Annamycin Details Soft tissue sarcoma, Solid tumor/s, Cancer, Lung Metastases, Sarcoma | Phase 1/2 Update | |
WP1122 Details Cancer, Glioblastoma, Brain tumor, Solid tumor/s | Phase 1/2 Initiation | |
WP1220 Details Cutaneous T cell lymphoma, Blood cancer, Cancer, T-cell lymphoma | Phase 1b Update | |
WP1066 Details Cancer, Brain tumor, Solid tumor/s, Glioma | Phase 1 Update | |
WP1122 Details COVID-19 | Phase 1a Update |